Botulinum toxin A treatment for primary hemifacial spasm -: A 10-year multicenter study
Botulinum toxin A treatment for primary hemifacial spasm -: A 10-year multicenter study
复制标题
DOI：
10.1001/archneur.59.3.418
复制
发表时间：
2002-03-01
影响因子：
--
通讯作者：
Berardelli, A
中科院分区：
文献类型：
--
作者：
Defazio, G;Abbruzzese, G;Berardelli, A
背景：A型肉毒杆菌毒素（BTX）是目前原发性面肌痉挛（HFS）的首选对症治疗方法，但其长期疗效和安全性尚不清楚。目的：评估BTX治疗原发性HF5的长期有效性和安全性。设计：回顾性审查治疗第1年和第10年的医疗记录。地点：意大利运动障碍研究的4所意大利大学中心的门诊诊所受试者组：65 名原发性 HFS 患者，定期接受 BTX 注射至少 10 年。主要结果指标：先前治疗引起的效果改善和质量的平均持续时间（使用患者自我评价量表测量）以及治疗第 1 和第 10 年不良反应的发生和持续时间。结果：使用与其他人使用的类似的每次治疗的平均 BTX 剂量，我们获得了 95% 的成功率第一年的缓解率和总体平均改善持续时间为 12.6 周。根据缓解率和平均改善持续时间衡量，BTX 在缓解原发性 HFS 症状方面的有效性在第一年和第 10 年保持不变。患者在第 1 年和第 10 年需要的 BTX 剂量在统计学上相似。治疗第 10 年，局部不良反应（包括上眼睑下垂、面部无力和复视）的发生率显着降低。结论：从长远来看，BTX 治疗可有效地持续缓解 I IFS 症状，且不良反应极小且短暂。
Background: Botulinum toxin A (BTX) is the currently preferred symptomatic treatment for primary hemifacial spasm (HFS), but its long-term efficacy and safety are not known.Objective: To assess the long-term effectiveness and safety of BTX in the treatment of primary HF5.Design: Retrospective review of medical records of the 1st and 10th years of treatment.Setting: Outpatient clinics of 4 Italian university centers in the Italian Movement Disorders Study Group.Participants: A series of 65 patients with primary, HFS who had received BTX injections regularly for at least 10 years.Main Outcome Measures: Mean duration of improvement and quality of the effect induced by the preceding treatment (measured using a patient self-evaluation scale) and occurrence and duration of adverse effects in the 1st and 10th years of treatment.Results: Using a mean BTX dose per treatment session similar to that used by others, we obtained a 95% response rate and an overall mean duration of improvement of 12.6 weeks during year 1. The effectiveness of BTX in relieving the symptoms of primary HFS, as measured by the response rate and average duration of improvement, remained unchanged in the 1st and 10th years. Patients needed statistically similar BTX doses in the 1st and 10th years. The rate of local adverse effects (including upper lid ptosis, facial weakness, and diplopia) diminished significantly in the 10th year of treatment.Conclusion: Treatment with BTX effectively induces sustained relief from symptoms of I IFS in the long term, with only minimal and transient adverse reactions.